Circassia Share Discussion Threads

[battlebus2] 26/2/2015 17:06

Anyone interested just download the results presentation from the media section on the circassia website, fascinating stuff and with massive potential for the patient.

[battlebus2] 26/2/2015 07:49

Progrees being made imv-- Strong balance sheet with GBP186.6 million cash and deposits at 31 December 2014 (31 December 2013: GBP30.6 million)

Steve Harris, Circassia's Chief Executive, said: "2014 has been transformational for Circassia. In March, we raised over GBP200 million through a successful IPO, and now have the funds to accelerate our late-stage clinical portfolio and establish the infrastructure to independently commercialise our first next generation allergy treatment. During the year, we made good progress towards meeting these goals. We completed recruitment for our phase III Cat-SPIRE registration study, which remains on track to report in H1 2016, and completed five further clinical trials across our portfolio. We are committed to bringing our innovative allergy products to market, and during the year we began to build our commercial organisation. With the US allergy immunotherapy marketplace opening up to new treatment approaches, we are well positioned to exploit the growing interest in this poorly served field."

[battlebus2] 25/2/2015 12:48

Strange thing to do before results tomorrow but Cannacord have reiterated their buy stance and target price of 323 today..

[battlebus2] 25/2/2015 11:56

Little bit of strength before tomorrows results.

[battlebus2] 23/2/2015 11:54

Results on Thursday 26th i believe..

[battlebus2] 16/2/2015 15:13

Added a few more for my sins :))

[battlebus2] 02/2/2015 11:15

I've been buying a few of these over the last while , seems the fall is overdone :))

[boros10] 01/9/2014 10:59

A possible threat to Circassia. Benchmark Holdings plc has announced deal which could have a material impact on its earnings in 3 or 4 years time. It has secured the manufacturing and distribution rights to award winning HypoCat a cat vaccine which neutralises the Fed d 1 protein, the primary cause of human allergic reaction to cats. The vaccine should reach market at the same time as Circassia's solution.A vaccine given to the cat seems to me to be far more preferable than injecting a child.At this lofty valuation, Circassia must be vulnerable to rival cat allergy solutions such as HypoCat. http://www.investegate.co.uk/benchmark-hlgs-plc--bmk-/rns/hypopet-agreement/201409010700164565Q/

[lennonsalive] 19/5/2014 07:39

Burning through that cash quickly

[rljaustin] 19/3/2014 08:29

The stagnant movement and valuation of Circassia seems to be benefitting AGY. Looks an interesting investment.

[algernon2] 14/3/2014 12:48

Roll on the fun.
I am in severe need of some fun.

[mirabeau] 13/3/2014 18:28

b141

Should be fun!

[barefoot141] 13/3/2014 09:19

Good morning Mira. Interesting to watch CIR over the next few days and what the AGY reaction is to the launch.

[mirabeau] 13/3/2014 07:53

Company

Circassia is a speciality biopharmaceutical company focused on the development of novel immunotherapies. These are designed to treat a range of common allergies and autoimmune conditions by controlling patients' inappropriate immune responses. Our most advanced product, Cat-SPIRE, has achieved highly impressive results in clinical studies, and is currently in the final phase of testing for cat allergy.

Circassia discovered and developed ToleroMune® technology and supported by our lead investors, Invesco Perpetual, Imperial Innovations and Lansdowne, we have made significant progress. We have expanded our portfolio of treatments, successfully completed numerous clinical studies and raised over £100 million in investment. Circassia also maintains strong links with allergy experts, and our joint venture with McMaster University (Hamilton, Canada), Adiga Life Sciences Inc, is pursuing promising new science in the field.

Circassia's ultimate ambition is to build a successful immunotherapy company, improving patients' lives around the world. In the short term, we plan to complete the development and launch of our first allergy treatment, Cat-SPIRE. To achieve this, we are building our commercial capabilities and advancing our phase III programme. With the support of our investors, Circassia is making good progress towards meeting its long-term goal.

[dusseldorf] 20/10/2006 10:49

anyone still holding Capricorn shares? I have some positive news for you!

I've been in communication with Brian Moritz regarding Dimension Resources and raised the issue of Capricorn and the shareholder blocking agreement and whether the same could happen at Dimension.

Given your shares are suspended/delisted he was happy to announce that hands have been shaken this week over a UK onshore gas project for Capricorn. Due diligence etc still to proceed but sounds like all is not lost...good luck

[bishopawn] 03/10/2006 15:45

Interest building again in EME ahead of newsflow.

[Abuse team] 03/10/2006 07:09

Post removed by ADVFN

[topvest] 30/9/2006 17:43

Yes, looks that way. Oh well, I suspect a deal will be done eventually given that Bruce Rowan owns a stack of shares and warrants at 1p. I've done quite nicely out of Capricorn having sold 90% of my original shares (subscribed in the original AIM offer) and made a very tidy profit, particularly for a company that never did anything! In reality this company was, at one stage, closely related to White Nile and CAMEC and we all know what sort of multi-bagger returns those companies have returned. Ultimately, the company has failed but all shareholders, other than those with massive holdings, have had the chance to get out at a profit! As i say, I'd be very surprised if this didn't come back one day, but I suspect Brian Moritz will have to move on - one gets the feeling that he must have fallen out with Bruce, reading between the lines! There is going to be c30 cancellations on Monday - a busy day for RNS releases! A question - are all 30 being cancelled, or if a deal is close and companies argue their case with the LSE do they get more time?

[Abuse team] 30/9/2006 16:52

Post removed by ADVFN

[topvest] 04/7/2006 16:02

Accounts received in the post today, so a little odd that no announcement. Key points seem to be:

- £175k of cash left at 31 Dec;
- Costs cut;
- Company to be wound up if no deal in place by 30 Sep
- Two transactions thrown out by > 25% shareholder; the first an alluvial fiamond project in South Africa and the second a natural gas and coal methane project in the UK.

It seems to me that it is probably Bruce Rowan and his connected company, Sunvest, that are refusing to approve the RTOs. BR and Sunvest hold 36%. Sounds to me like BR and Brian Moritz have fallen out big time. If this is the case, then I suspect this may be heading for an AIM cancellation, or some shareholder trouble. Personally, I would rather the AIM listing were cancelled and Bruce Rowan re-float this in a year or two. He still has a very large number of warrants at a penny and so it is in his interests to use this shell company. If its a choice between Bruce Rowan and Brian Moritz then I would go with the former. Any thoughts?

[smiler27] 01/5/2006 14:44

Investors will start looking at Moritz's other interest in the shape of DMR soon which is a snip at 0.35 pence. Brian Moritz has got something big lined up there.

[bozzy_s] 03/4/2006 08:35

Investing companies

An investing company is any AIM company which, in the opinion of the LSE, has as a primary business the investing of its funds in the securities of other companies or the acquisition of a particular business. Although the LSE wants to continue to encourage investing companies to join AIM, it recognises the need to regulate the quality of such companies in order to protect the interests of shareholders and thereputation of AIM as a whole.

The LSE is, therefore, proposing that a new Rule 8 be inserted into the AIMRules specifically tailored for investing companies, under which:

the admission of an applicant, which is an investing company, will be conditional on it raising at least £3 million in cash via an equity fundraising on, or immediately before, admission; qan investing company must within 12 months of its admission, make an acquisition or acquisitions which, in aggregate, exceed 50% in each of the relevant class tests (disregarding any interest in another investing company); and an AIM company which becomes an investing company must, within twelve months of becoming an investing company, make an acquisition or acquisitions which constitute a reverse takeover.

It is proposed that if the investing company does not make the necessary acquisitions within the prescribed twelve month period its AIM securities will be automatically suspended. The suspended securities will only be restored to trading if the company makes a requisite acquisition within six months following suspension. Failure to make a requisite admission within six months from its suspension will result in the LSE cancelling admission.

[trevor1959] 13/3/2006 21:10

Suspect this might apply to CIR:

mall Talk: Cash shell minnows to be squeezed out of AIM
By Michael Jivkov
Published: 06 March 2006
Up to fifty companies listed on London's junior market face having their shares suspended at the end of the month. By the 1 April deadline, all remaining AIM-listed cash shells with less than £3m in the bank must complete an acquisition. Otherwise trading of their shares will be halted and, at a later date, de-listed.

The London Stock Exchange, which runs AIM, decided last March that it wanted to stem the steady stream of tiny shell company floats on the junior market by giving them only a small window in which to make an acquisition. Of the fifty remaining shells - most of which have less than £1m on their balance sheet - a good number are likely to be working on deals ahead of the cut-off point. If they can demonstrate to the Exchange that they are in the middle of a deal they will avoid suspension. But those companies that have left it too late to comply with the rules face an uphill struggle. As the deadline approaches the value of their shares is likely to decline. Further, any target company they are in talks to buy will be aware of the looming deadline and will certainly push for a better deal for its own shareholders. The biggest risk of all for cash shell investors is that their boards rush into an acquisition that they subsequently regret, wiping out shareholder value in the process

[pork belly] 07/2/2006 20:04

Capricorn Resources Shrs Move On 'Momentum'

Monday, February 06, 2006 5:58:24 AM ET
Dow Jones Newswires

0938 GMT [Dow Jones] Capricorn Resources (CIR.LN) shares gain 90% to 2.375p on "momentum buying," says a trader. Notes the shares have "not done anything for ages." No company-specific news moving the shares says the trader, just "fear-and-greed mentality." Adds, "it's a pretty thin market, there's a bit of a squeeze on." Points out that shares are "just going along with the rest of the sector." (JZR)